Literature DB >> 11028442

Mineral density and bone strength are dissociated in long bones of rat osteopetrotic mutations.

J Tuukkanen1, A Koivukangas, T Jämsä, K Sundquist, C A Mackay, S C Marks.   

Abstract

Bone mineral density (BMD) and mechanical strength generally show strong positive correlations. However, osteopetrosis is a metabolic bone disease with increased skeletal density radiographically and increased risk of fracture. We have evaluated mechanical strength and mineral density in three osteopetrotic mutations in the rat (incisors-absent [ia/ia], osteopetrosis [op/op], and toothless [tl/tl]) to test the hypothesis that reduced bone resorption in one or more of these mutations results in weaker bones in the presence of greater mineral density and skeletal mass. Peripheral quantitative computed tomography (pQCT) was used to analyze BMD and cross-sectional geometry in the tibial diaphysis and metaphysis as well as the femoral diaphysis and femoral neck. The bending breaking force of tibial and femoral midshafts was obtained using the three-point bending test and femoral neck strength was tested by axial loading. Osteopetrotic mutants were significantly smaller than their normal littermates (NLMs) in each stock. The pQCT analysis showed that BMD and bone mineral content (BMC) were higher than or equal to NLMs in all skeletal sites measured in the osteopetrotic mutants. However, the mechanical breaking force was equal to or lower than their NLMs in all sites. The cross-sectional structure of long bone shafts was markedly different in osteopetrotic mutants, having a thin cortex and a medullary area filled with primary trabecular bone. These results indicate that osteopetrotic mutations in the rat increase bone density and decrease bone strength. The tibial diaphysis was significantly weaker in tl/tl and ia/ia mutants and the tibial metaphysis showed the greatest increase in BMD in all mutants. These data are another illustration that an increased BMD does not necessarily lead to stronger bones.

Entities:  

Mesh:

Year:  2000        PMID: 11028442     DOI: 10.1359/jbmr.2000.15.10.1905

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  13 in total

1.  Meox2Cre-mediated disruption of CSF-1 leads to osteopetrosis and osteocyte defects.

Authors:  Stephen E Harris; Mary MacDougall; Diane Horn; Kathleen Woodruff; Stephanie N Zimmer; Vivienne I Rebel; Roberto Fajardo; Jian Q Feng; Jelica Gluhak-Heinrich; Marie A Harris; Sherry Abboud Werner
Journal:  Bone       Date:  2011-09-20       Impact factor: 4.398

2.  Quantitative percussion diagnostics and bone density analysis of the implant-bone interface in a pre- and postmortem human subject.

Authors:  Cherilyn G Sheets; Dee Dee Hui; Vaibhav Bajaj; James C Earthman
Journal:  Int J Oral Maxillofac Implants       Date:  2013 Nov-Dec       Impact factor: 2.804

3.  Adiponectin is associated with bone strength and fracture history in paralyzed men with spinal cord injury.

Authors:  C O Tan; R A Battaglino; A L Doherty; R Gupta; A A Lazzari; E Garshick; R Zafonte; L R Morse
Journal:  Osteoporos Int       Date:  2014-07-01       Impact factor: 4.507

4.  Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.

Authors:  Douglas A Corley; Ai Kubo; Wei Zhao; Charles Quesenberry
Journal:  Gastroenterology       Date:  2010-03-27       Impact factor: 22.682

5.  Using three-point bending to evaluate tibia bone strength in ovariectomized young mice.

Authors:  Charles Deckard; Azida Walker; Brent J F Hill
Journal:  J Biol Phys       Date:  2017-01-28       Impact factor: 1.365

6.  Proton pump inhibitors' use and risk of hip fracture: a systematic review and meta-analysis.

Authors:  Salman Hussain; Ali Nasir Siddiqui; Anwar Habib; Md Sarfaraj Hussain; Abul Kalam Najmi
Journal:  Rheumatol Int       Date:  2018-08-29       Impact factor: 2.631

7.  Bone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysis.

Authors:  Si-Dong Yang; Qian Chen; Hai-Kun Wei; Feng Zhang; Da-Long Yang; Yong Shen; Wen-Yuan Ding
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 8.  Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned.

Authors:  Matthew T Drake; Bart L Clarke; Merry Jo Oursler; Sundeep Khosla
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

9.  Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate.

Authors:  Larry Pederson; Ming Ruan; Jennifer J Westendorf; Sundeep Khosla; Merry Jo Oursler
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

10.  Effects of hypothalamic leptin gene therapy on osteopetrosis in leptin-deficient mice.

Authors:  Kenneth A Philbrick; Stephen A Martin; Amy R Colagiovanni; Adam J Branscum; Russell T Turner; Urszula T Iwaniec
Journal:  J Endocrinol       Date:  2017-11-30       Impact factor: 4.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.